Quan Vu - Mar 3, 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Financial Officer
Signature
/s/ Quan Vu
Stock symbol
MNPR
Transactions as of
Mar 3, 2025
Transactions value $
$0
Form type
4
Date filed
3/5/2025, 04:06 PM
Previous filing
Mar 10, 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Stock Options Award $0 +25K $0.00 25K Mar 3, 2025 Common Stock 25K $30.93 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 3, 2025, the reporting person was granted 25,000 stock options, vesting 6/48ths (15,625 shares) on September 2, 2025, and 1/48th every month thereafter until the stock option is fully vested on March 3, 2029.